By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BIND Therapeutics 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-491-3400 Fax: 617-491-0351


Company News
BIND Therapeutics (BIND) Amends Credit Facility From Hercules Technology III, L.P. To Accelerate Accurin Pipeline Growth 1/26/2015 10:28:59 AM
BIND Therapeutics (BIND) Co-Founder Publishes Nanotechnology Article In JAMA 1/22/2015 8:47:17 AM
BIND Therapeutics (BIND) Provides Clinical Update For BIND-014 And 2015 Strategic Overview 1/8/2015 2:15:26 PM
BIND Therapeutics (BIND) To Present At Oppenheimer 25th Annual Healthcare Conference 11/26/2014 8:37:21 AM
BIND Therapeutics (BIND) Presents Positive Phase 2 Results Highlighting Potential Of BIND-014 As Novel Anti-Cancer Treatment At Q3W Dosing Schedule For Patients With Non-Small Cell Lung Cancer At 26th EORTC-NCI-AACR Annual Symposium 11/19/2014 10:05:24 AM
BIND Therapeutics (BIND) Reports Third Quarter 2014 Financial Results And Provides Corporate Update 11/6/2014 11:19:43 AM
BIND Therapeutics (BIND) Announces Agreement With Merck & Co. (MRK) To Develop Targeted Accurin™ Nanomedicines For Oncology 11/6/2014 9:00:56 AM
BIND Therapeutics (BIND) Appoints Hagop Youssoufian, M.Sc., M.D. As Chief Medical Officer 11/4/2014 10:03:35 AM
BIND Therapeutics (BIND) Announces Availability Of Abstract With Preliminary Data From Phase 2 Study Of BIND-014 In Non-Small Cell Lung Cancer 10/30/2014 11:17:31 AM
BIND Therapeutics (BIND) To Present At November Healthcare Conferences 10/29/2014 9:13:36 AM